Pages that link to "Q69990612"

The following pages link to Expression of normal myeloid-associated antigens by acute leukemia cells (Q69990612):

Displaying 36 items.

• Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances (Q26775720) (← links)
• Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia (Q27853019) (← links)
• P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients (Q33472987) (← links)
• Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group (Q33601710) (← links)
• Gemtuzumab ozogamicin (Q34340421) (← links)
• Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed (Q34567322) (← links)
• Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. (Q35146288) (← links)
• 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia (Q35232360) (← links)
• Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia (Q35591409) (← links)
• Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. (Q35909648) (← links)
• Acute myeloid leukemia stem cells and CD33-targeted immunotherapy (Q36058588) (← links)
• CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia (Q36279306) (← links)
• A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia (Q36928318) (← links)
• Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin (Q36932014) (← links)
• Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts (Q36989586) (← links)
• Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia (Q37381414) (← links)
• Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. (Q37512086) (← links)
• Antibody-based therapy of leukaemia (Q37605247) (← links)
• Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia (Q38109541) (← links)
• Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments (Q38155455) (← links)
• Novel drugs for older patients with acute myeloid leukemia (Q38241761) (← links)
• Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates (Q38262066) (← links)
• Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery (Q38383345) (← links)
• Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. (Q38569175) (← links)
• Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system (Q39108154) (← links)
• Routine immunophenotyping of acute leukaemias (Q39550856) (← links)
• Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas (Q40415354) (← links)
• Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia (Q41558781) (← links)
• Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates. (Q47330613) (← links)
• FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. (Q52591098) (← links)
• Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. (Q52668213) (← links)
• Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia (Q57045406) (← links)
• DNA damaging agent-based antibody-drug conjugates for cancer therapy (Q57192403) (← links)
• Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression (Q81721684) (← links)
• Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? (Q89835052) (← links)
• The expansion of targetable biomarkers for CAR T cell therapy (Q90382740) (← links)